Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive breast cancer subtype with limited targeted treatment options. Second mitochondrial activator of caspases (SMAC) mimetics represent a promising therapeutic class for TNBC patients, although they have yet to be approved clinically. Screening a re...
E. Brown, Paige Jensen, Chieh-Hsiang Yang et al.· bioRxiv· 0 citations
While immunotherapy has great potential to eradicate tumors, success in metastatic breast cancer is limited. Bone metastasis, the most common site for breast cancer metastasis, has been associated with weakened anti-tumor immunity, both in the bone and in other metastatic sites. Additional strategies promoting anti-tum...
Clint H. Valencia, Marija S. Nadjsombati, T. Phạm et al.· bioRxiv· 0 citations
Functional precision oncology aims to guide therapy selection by directly measuring drug sensitivity in patient-derived cancer samples. However, most existing functional assays require prolonged cell expansion limiting their feasibility for time-sensitive clinical decision-making. We evaluated whether multiparame...
Edward R. Polanco, Tarek E. Moustafa, Ozlen Balcioglu et al.· BMC Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.